+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

  • ID: 4767160
  • Drug Pipelines
  • 214 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cadrock Pty Ltd
  • Cynata Therapeutics Ltd
  • Kowa Co Ltd
  • Orion Corp
  • Reven Pharmaceuticals Inc
  • MORE
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

This latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 13, 6, 3, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Cadrock Pty Ltd
  • Cynata Therapeutics Ltd
  • Kowa Co Ltd
  • Orion Corp
  • Reven Pharmaceuticals Inc
  • MORE
Introduction

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cadrock Pty Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cynata Therapeutics Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by DalCor Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Pharmaceutical Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Kowa Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Orion Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Reven Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Supernus Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Virtual Drug Development Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ascendia Pharmaceuticals LLC
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Bayer AG
  • Cadrock Pty Ltd
  • Capricor Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • CSL Ltd
  • Cynata Therapeutics Ltd
  • DalCor Pharmaceuticals Inc
  • Gilead Sciences Inc
  • Hemostemix Inc
  • Human Stem Cells Institute
  • Idorsia Pharmaceutical Ltd
  • Kowa Co Ltd
  • LipimetiX Development Inc
  • Livzon Pharmaceutical Group Co Ltd
  • MedImmune LLC
  • Orion Corp
  • Proteon Therapeutics Inc
  • Resverlogix Corp
  • Reven Pharmaceuticals Inc
  • Supernus Pharmaceuticals Inc
  • The Medicines Company
  • Verseon Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • Virtual Drug Development Inc
  • XyloCor Therapeutics Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767160
Adroll
adroll